EX-99.1 2 abbv-20250630nonxgaapxex991.htm EX-99.1 Document

AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
 
(in millions, except per share data)Quarter Ended June 30, 2025Full-Year Ended December 31, 2025
Acquired IPR&D and Milestones ExpenseAdjusted Diluted EPS RangeAcquired IPR&D and Milestones ExpenseAdjusted Diluted EPS Range
LowHighLowHigh
Previously announced guidance excluding Q2 2025 acquired IPR&D and milestones expense
$— $3.26 $3.30 $248 $12.09 $12.29 
Q2 2025 acquired IPR&D and milestones expense823 (0.42)(0.42)823 (0.42)(0.42)
Guidance including Q2 2025 acquired IPR&D and milestones expensea
$823 $2.84 $2.88 $1,071 $11.67 $11.87 

a    The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2025, as both cannot be reliably forecasted.





    1